Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 20/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 20/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 20/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291710 | 1.00 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1460392 | 0.95 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1565877 | 0.94 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1566376 | 0.93 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1566481 | 0.91 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1566482 | 0.91 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1566429 | 0.90 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1566438 | 0.90 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1565622 | 0.89 | CYBB (1.00) | CYBBNOX5NOX4NOX1 | |
| SCHEMBL1459191 | 0.87 | CYBB (1.00) | CYBBNOX5NOX4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | claimed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | claimed |
| EP-2483271-B1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-08-16 | — | — | EP | claimed |
| US-9394306-B2 | Pyrazoline dione derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-07-19 | — | — | US | claimed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | claimed |
| US-20120172352-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-07-05 | — | — | US | claimed |
| EP-2305679-A1 | Pyrazoline dione derivatives as nadph oxidase inhibitors | GenKyoTex SA (CH) | 2011-04-06 | — | — | EP | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-10-31 | — | — | US | disclosed |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-06-18 | — | — | US | disclosed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20120172352-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20120172352-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-2305679-A1 | Pyrazoline dione derivatives as nadph oxidase inhibitors | GenKyoTex SA (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305679-A1 | Pyrazoline dione derivatives as nadph oxidase inhibitors | GenKyoTex SA (CH) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011036651-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | CYBB 6/4885NOX5 2/4885NOX4 3/4885 |
| US-20120172352-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | CYBB 3/4885NOX5 2/4885NOX4 4/4885 |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | NOX1, NOX5, NOX3 | CYBB 6/4885NOX5 2/4885NOX4 5/4885 |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | CYBB 6/4885NOX5 2/4885NOX4 5/4885 |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | CYBB 6/4885NOX5 2/4885NOX4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.